Articles

Women with higher circulating carotenoid levels are at a reduced risk of breast cancer according to recent study results.

For patients with HER2-postive early-stage breast cancer, 1 year of adjuvant trastuzumab should remain the standard of care.

The FDA recently approved abiraterone acetate, a drug that decreases the production of testosterone, for use in treating men with metastatic castration-resistant prostate cancer prior to receiving chemotherapy.

The question of potential overtreatment among women with breast cancer has been raised due to recent studies showing an increase in these patients choosing the more aggressive contralateral prophylactic mastectomy.

By adding tomosynthesis, a 3-dimensional (3-D) breast imaging technology, to standard digital mammography, radiologists’ diagnostic accuracy increases while false-positive recall rates decrease

New study findings related to the drug metformin may aid researchers as they study the use of existing medications to treat different or new diseases.

National investment in clinical cancer research on prevention, screening, survival, and quality of life for patients with cancer is reflected in the large number of advances featured in this year’s report.

For patients with prostate cancer that had spread to the bone, a new drug exhibited remarkable and quick effects.

Each year, physicians discontinue more than 85,000 medications; however, this information is not always shared with the pharmacists involved.

Results from a new study show that when compared with beginning therapy shortly after diagnosis, women who wait more than 60 days to begin treatment for advanced breast cancer face significantly higher risks of dying.